Zura Bio(ZURA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ZURA Zura Bio

已收盘 07-15 16:00:00 EDT

1.30

+0.00

0.00%

盘后1.30

+0.000.00%

19:33 EDT

最高1.36	最低1.26	成交量21.95万
今开1.32	昨收1.30	日振幅7.69%
总市值8,044万	流通市值2,555万	总股本6,187万
成交额28.57万	换手率1.12%	流通股本1,965万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ZURA","market":"US","secType":"STK","nameCN":"Zura Bio","latestPrice":1.3,"timestamp":1752609600000,"preClose":1.3,"halted":0,"volume":219467,"hourTrading":{"tag":"盘后","latestPrice":1.3,"preClose":1.3,"latestTime":"19:33 EDT","volume":259,"amount":336.6789,"timestamp":1752622424408},"delay":0,"floatShares":19651876,"shares":61874998,"eps":-0.717206,"marketStatus":"已收盘","change":0,"latestTime":"07-15 16:00:00 EDT","open":1.32,"high":1.36,"low":1.26,"amount":285728.5863735,"amplitude":0.076923,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.717206,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1752652800000},"marketStatusCode":5,"adr":0,"exchange":"NASDAQ","adjPreClose":1.3,"preHourTrading":{"tag":"盘前","latestPrice":1.33,"preClose":1.3,"latestTime":"09:25 EDT","volume":605,"amount":789.625067,"timestamp":1752585956756},"postHourTrading":{"tag":"盘后","latestPrice":1.3,"preClose":1.3,"latestTime":"19:33 EDT","volume":259,"amount":336.6789,"timestamp":1752622424408},"volumeRatio":0.30646,"impliedVol":0.5813,"impliedVolPercentile":0.1528},"requestUrl":"/m/hq/s/ZURA","defaultTab":"news","newsList":[{"id":"2550968160","title":"Zura Bio Limited盘中异动 股价大跌5.04%报1.32美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2550968160","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550968160?lang=zh_cn&edition=full","pubTime":"2025-07-12 00:13","pubTimestamp":1752250398,"startTime":"0","endTime":"0","summary":"北京时间2025年07月12日00时13分，Zura Bio Limited股票出现异动，股价大幅下挫5.04%。截至发稿，该股报1.32美元/股，成交量9.8682万股，换手率0.16%，振幅4.32%。Zura Bio Limited股票所在的生物技术行业中，整体跌幅为0.26%。Zura Bio Limited公司简介：Zura Bio Ltd 是一家临床阶段的多资产免疫学公司，致力于开发针对自身免疫和炎症性疾病的新型双通路抗体。该公司正在开发 tibulizumab 和 torudokimab 的治疗适应症组合，旨在证明它们在自身免疫和炎症性疾病中的疗效、安全性和给药便利性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250712001318a44539ab&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250712001318a44539ab&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ZURA"],"gpt_icon":0},{"id":"2550625923","title":"Zura Bio Limited盘中异动 早盘股价大涨5.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2550625923","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550625923?lang=zh_cn&edition=full","pubTime":"2025-07-10 21:31","pubTimestamp":1752154277,"startTime":"0","endTime":"0","summary":"北京时间2025年07月10日21时31分，Zura Bio Limited股票出现波动，股价快速拉升5.13%。截至发稿，该股报1.42美元/股，成交量1.1955万股，换手率0.02%，振幅2.22%。Zura Bio Limited股票所在的生物技术行业中，整体跌幅为0.14%。Zura Bio Limited公司简介：Zura Bio Ltd 是一家临床阶段的多资产免疫学公司，致力于开发针对自身免疫和炎症性疾病的新型双通路抗体。该公司正在开发 tibulizumab 和 torudokimab 的治疗适应症组合，旨在证明它们在自身免疫和炎症性疾病中的疗效、安全性和给药便利性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710213117a442b790&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710213117a442b790&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ZURA","BK4139"],"gpt_icon":0},{"id":"2550527188","title":"Zura Bio Limited盘中异动 下午盘股价大涨5.00%报1.16美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2550527188","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550527188?lang=zh_cn&edition=full","pubTime":"2025-07-09 02:21","pubTimestamp":1751998909,"startTime":"0","endTime":"0","summary":"北京时间2025年07月09日02时21分，Zura Bio Limited股票出现波动，股价快速上涨5.00%。截至发稿，该股报1.16美元/股，成交量21.2763万股，换手率0.34%，振幅6.30%。Zura Bio Limited股票所在的生物技术行业中，整体涨幅为1.18%。Zura Bio Limited公司简介：Zura Bio Ltd 是一家临床阶段的多资产免疫学公司，致力于开发针对自身免疫和炎症性疾病的新型双通路抗体。该公司正在开发 tibulizumab 和 torudokimab 的治疗适应症组合，旨在证明它们在自身免疫和炎症性疾病中的疗效、安全性和给药便利性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709022149a69da3a6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709022149a69da3a6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ZURA","BK4139"],"gpt_icon":0},{"id":"2549530494","title":"Zura Bio Limited盘中异动 早盘股价大涨5.31%报1.19美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2549530494","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549530494?lang=zh_cn&edition=full","pubTime":"2025-07-07 21:32","pubTimestamp":1751895148,"startTime":"0","endTime":"0","summary":"北京时间2025年07月07日21时32分，Zura Bio Limited股票出现波动，股价快速拉升5.31%。截至发稿，该股报1.19美元/股，成交量2.8235万股，换手率0.05%，振幅0.00%。Zura Bio Limited股票所在的生物技术行业中，整体跌幅为0.09%。Zura Bio Limited公司简介：Zura Bio Ltd 是一家临床阶段的多资产免疫学公司，致力于开发针对自身免疫和炎症性疾病的新型双通路抗体。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250707213228a43bf699&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250707213228a43bf699&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ZURA","BK4139"],"gpt_icon":0},{"id":"2548915816","title":"Zura Bio Limited盘中异动 股价大涨5.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2548915816","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548915816?lang=zh_cn&edition=full","pubTime":"2025-07-02 21:32","pubTimestamp":1751463175,"startTime":"0","endTime":"0","summary":"北京时间2025年07月02日21时32分，Zura Bio Limited股票出现异动，股价急速拉升5.24%。截至发稿，该股报1.11美元/股，成交量9926股，换手率0.02%，振幅3.81%。Zura Bio Limited股票所在的生物技术行业中，整体跌幅为0.22%。Zura Bio Limited公司简介：Zura Bio Ltd 是一家临床阶段的多资产免疫学公司，致力于开发针对自身免疫和炎症性疾病的新型双通路抗体。该公司正在开发 tibulizumab 和 torudokimab 的治疗适应症组合，旨在证明它们在自身免疫和炎症性疾病中的疗效、安全性和给药便利性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507022132559533fd78&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507022132559533fd78&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ZURA"],"gpt_icon":0},{"id":"2547097035","title":"Zura Bio Limited盘中异动 早盘快速上涨7.62%","url":"https://stock-news.laohu8.com/highlight/detail?id=2547097035","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2547097035?lang=zh_cn&edition=full","pubTime":"2025-06-30 21:31","pubTimestamp":1751290263,"startTime":"0","endTime":"0","summary":"北京时间2025年06月30日21时31分，Zura Bio Limited股票出现波动，股价急速拉升7.62%。截至发稿，该股报1.13美元/股，成交量1.0915万股，换手率0.02%，振幅0.00%。Zura Bio Limited股票所在的生物技术行业中，整体涨幅为0.06%。Zura Bio Limited公司简介：Zura Bio Ltd 是一家临床阶段的多资产免疫学公司，致力于开发针对自身免疫和炎症性疾病的新型双通路抗体。该公司正在开发 tibulizumab 和 torudokimab 的治疗适应症组合，旨在证明它们在自身免疫和炎症性疾病中的疗效、安全性和给药便利性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250630213103a4c6c3da&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250630213103a4c6c3da&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ZURA","BK4139"],"gpt_icon":0},{"id":"2546264417","title":"Zura Bio Limited盘中异动 下午盘股价大跌5.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2546264417","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546264417?lang=zh_cn&edition=full","pubTime":"2025-06-28 02:30","pubTimestamp":1751049015,"startTime":"0","endTime":"0","summary":"北京时间2025年06月28日02时30分，Zura Bio Limited股票出现波动，股价快速跳水5.22%。截至发稿，该股报1.09美元/股，成交量16.2412万股，换手率0.26%，振幅6.52%。Zura Bio Limited股票所在的生物技术行业中，整体跌幅为0.60%。Zura Bio Limited公司简介：Zura Bio Ltd 是一家临床阶段的多资产免疫学公司，致力于开发针对自身免疫和炎症性疾病的新型双通路抗体。该公司正在开发 tibulizumab 和 torudokimab 的治疗适应症组合，旨在证明它们在自身免疫和炎症性疾病中的疗效、安全性和给药便利性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250628023015a4c1b8a6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250628023015a4c1b8a6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ZURA"],"gpt_icon":0},{"id":"2546308817","title":"Zura Bio Limited盘中异动 早盘快速下跌5.08%报1.12美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2546308817","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546308817?lang=zh_cn&edition=full","pubTime":"2025-06-26 23:02","pubTimestamp":1750950126,"startTime":"0","endTime":"0","summary":"北京时间2025年06月26日23时02分，Zura Bio Limited股票出现波动，股价大幅跳水5.08%。截至发稿，该股报1.12美元/股，成交量5.586万股，换手率0.09%，振幅6.33%。Zura Bio Limited股票所在的生物技术行业中，整体涨幅为0.20%。Zura Bio Limited公司简介：Zura Bio Ltd 是一家临床阶段的多资产免疫学公司，致力于开发针对自身免疫和炎症性疾病的新型双通路抗体。该公司正在开发 tibulizumab 和 torudokimab 的治疗适应症组合，旨在证明它们在自身免疫和炎症性疾病中的疗效、安全性和给药便利性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250626230206a71f1966&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250626230206a71f1966&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ZURA","BK4139"],"gpt_icon":0},{"id":"2545231994","title":"Zura Bio Limited盘中异动 快速上涨5.36%报1.18美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2545231994","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2545231994?lang=zh_cn&edition=full","pubTime":"2025-06-24 23:11","pubTimestamp":1750777883,"startTime":"0","endTime":"0","summary":"北京时间2025年06月24日23时11分，Zura Bio Limited股票出现波动，股价大幅上涨5.36%。截至发稿，该股报1.18美元/股，成交量7.1059万股，换手率0.11%，振幅4.46%。Zura Bio Limited股票所在的生物技术行业中，整体涨幅为1.40%。Zura Bio Limited公司简介：Zura Bio Ltd 是一家临床阶段的多资产免疫学公司，致力于开发针对自身免疫和炎症性疾病的新型双通路抗体。该公司正在开发 tibulizumab 和 torudokimab 的治疗适应症组合，旨在证明它们在自身免疫和炎症性疾病中的疗效、安全性和给药便利性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250624231123a4bbb807&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250624231123a4bbb807&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ZURA"],"gpt_icon":0},{"id":"2544422990","title":"Zura Bio Limited盘中异动 股价大跌5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2544422990","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2544422990?lang=zh_cn&edition=full","pubTime":"2025-06-18 04:01","pubTimestamp":1750190469,"startTime":"0","endTime":"0","summary":"北京时间2025年06月18日04时01分，Zura Bio Limited股票出现波动，股价急速下挫5.00%。截至发稿，该股报1.14美元/股，成交量28.1265万股，换手率0.45%，振幅4.58%。Zura Bio Limited股票所在的生物技术行业中，整体跌幅为1.71%。Zura Bio Limited公司简介：Zura Bio Ltd 是一家临床阶段的多资产免疫学公司，致力于开发针对自身免疫和炎症性疾病的新型双通路抗体。该公司正在开发 tibulizumab 和 torudokimab 的治疗适应症组合，旨在证明它们在自身免疫和炎症性疾病中的疗效、安全性和给药便利性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250618040109a70ef6a3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250618040109a70ef6a3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ZURA"],"gpt_icon":0},{"id":"2542343875","title":"Zura Bio Limited盘中异动 早盘股价大涨5.60%","url":"https://stock-news.laohu8.com/highlight/detail?id=2542343875","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2542343875?lang=zh_cn&edition=full","pubTime":"2025-06-10 22:05","pubTimestamp":1749564328,"startTime":"0","endTime":"0","summary":"北京时间2025年06月10日22时05分，Zura Bio Limited股票出现波动，股价急速拉升5.60%。截至发稿，该股报1.32美元/股，成交量11.9111万股，换手率0.19%，振幅4.40%。Zura Bio Limited股票所在的生物技术行业中，整体涨幅为0.53%。Zura Bio Limited公司简介：Zura Bio Ltd 是一家临床阶段的多资产免疫学公司，致力于开发针对自身免疫和炎症性疾病的新型双通路抗体。该公司正在开发 tibulizumab 和 torudokimab 的治疗适应症组合，旨在证明它们在自身免疫和炎症性疾病中的疗效、安全性和给药便利性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250610220529a4a20fa9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250610220529a4a20fa9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ZURA"],"gpt_icon":0},{"id":"2540067833","title":"Zura Bio Limited盘中异动 快速上涨5.58%","url":"https://stock-news.laohu8.com/highlight/detail?id=2540067833","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2540067833?lang=zh_cn&edition=full","pubTime":"2025-06-04 23:17","pubTimestamp":1749050277,"startTime":"0","endTime":"0","summary":"北京时间2025年06月04日23时17分，Zura Bio Limited股票出现波动，股价快速上涨5.58%。Zura Bio Limited股票所在的生物技术行业中，整体涨幅为0.70%。Zura Bio Limited公司简介：Zura Bio Ltd 是一家临床阶段的多资产免疫学公司，致力于开发针对自身免疫和炎症性疾病的新型双通路抗体。该公司正在开发 tibulizumab 和 torudokimab 的治疗适应症组合，旨在证明它们在自身免疫和炎症性疾病中的疗效、安全性和给药便利性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506042317589771a71d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506042317589771a71d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ZURA"],"gpt_icon":0},{"id":"2540708865","title":"Zura Bio Limited盘中异动 早盘股价大涨5.45%报1.07美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2540708865","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2540708865?lang=zh_cn&edition=full","pubTime":"2025-06-03 22:34","pubTimestamp":1748961293,"startTime":"0","endTime":"0","summary":"北京时间2025年06月03日22时34分，Zura Bio Limited股票出现波动，股价快速拉升5.45%。截至发稿，该股报1.07美元/股，成交量12.5918万股，换手率0.20%，振幅6.67%。Zura Bio Limited股票所在的生物技术行业中，整体跌幅为0.12%。Zura Bio Limited公司简介：Zura Bio Ltd 是一家临床阶段的多资产免疫学公司，致力于开发针对自身免疫和炎症性疾病的新型双通路抗体。该公司正在开发 tibulizumab 和 torudokimab 的治疗适应症组合，旨在证明它们在自身免疫和炎症性疾病中的疗效、安全性和给药便利性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025060322345497700536&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025060322345497700536&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ZURA"],"gpt_icon":0},{"id":"2539498261","title":"Zura Bio Limited盘中异动 早盘急速拉升6.28%报1.060美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2539498261","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2539498261?lang=zh_cn&edition=full","pubTime":"2025-05-29 22:57","pubTimestamp":1748530666,"startTime":"0","endTime":"0","summary":"北京时间2025年05月29日22时57分，Zura Bio Limited股票出现异动，股价大幅拉升6.28%。截至发稿，该股报1.060美元/股，成交量15.0231万股，换手率0.24%，振幅4.01%。Zura Bio Limited股票所在的生物技术行业中，整体涨幅为0.76%。Zura Bio Limited公司简介：Zura Bio Ltd 是一家临床阶段的多资产免疫学公司，致力于开发针对自身免疫和炎症性疾病的新型双通路抗体。该公司正在开发 tibulizumab 和 torudokimab 的治疗适应症组合，旨在证明它们在自身免疫和炎症性疾病中的疗效、安全性和给药便利性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250529225746a49182c6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250529225746a49182c6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ZURA"],"gpt_icon":0},{"id":"2537294930","title":"Zura Bio Limited盘中异动 股价大跌5.61%报1.01美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2537294930","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537294930?lang=zh_cn&edition=full","pubTime":"2025-05-22 00:32","pubTimestamp":1747845138,"startTime":"0","endTime":"0","summary":"北京时间2025年05月22日00时32分，Zura Bio Limited股票出现异动，股价大幅下跌5.61%。截至发稿，该股报1.01美元/股，成交量20.3969万股，换手率0.33%，振幅6.54%。Zura Bio Limited股票所在的生物技术行业中，整体跌幅为0.33%。Zura Bio Limited公司简介：Zura Bio Ltd 是一家临床阶段的多资产免疫学公司，致力于开发针对自身免疫和炎症性疾病的新型双通路抗体。该公司正在开发 tibulizumab 和 torudokimab 的治疗适应症组合，旨在证明它们在自身免疫和炎症性疾病中的疗效、安全性和给药便利性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505220032189760fcfc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505220032189760fcfc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ZURA","BK4139"],"gpt_icon":0},{"id":"2536582446","title":"Zura Bio Limited2025财年第一财季实现净利润-17.44百万美元，同比减少2289.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2536582446","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2536582446?lang=zh_cn&edition=full","pubTime":"2025-05-18 00:00","pubTimestamp":1747497611,"startTime":"0","endTime":"0","summary":"5月18日，Zura Bio Limited公布财报，公告显示公司2025财年第一财季净利润为-17.44百万美元，同比减少2289.04%；其中营业收入为0.00美元，每股基本收益为-0.19美元。从资产负债表来看，Zura Bio Limited总负债21.09百万美元，其中短期债务0.00美元，资产负债比为0.09，流动比率为0.09。机构评级：截至2025年5月18日，当前有6家机构对Zura Bio Limited目标价做出预测，其中目标均价为13.67美元，其中最低目标价为3.00美元，最高目标价为26.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250518000023a6e2d79c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250518000023a6e2d79c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ZURA"],"gpt_icon":0},{"id":"2536346241","title":"Zura Bio Limited盘中异动 下午盘快速下挫5.00%报1.14美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2536346241","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2536346241?lang=zh_cn&edition=full","pubTime":"2025-05-17 01:27","pubTimestamp":1747416428,"startTime":"0","endTime":"0","summary":"北京时间2025年05月17日01时27分，Zura Bio Limited股票出现异动，股价急速下跌5.00%。截至发稿，该股报1.14美元/股，成交量94.3261万股，换手率1.52%，振幅7.50%。Zura Bio Limited股票所在的生物技术行业中，整体涨幅为0.55%。Zura Bio Limited公司简介：Zura Bio Ltd 是一家临床阶段的多资产免疫学公司，致力于开发针对自身免疫和炎症性疾病的新型双通路抗体。该公司正在开发 tibulizumab 和 torudokimab 的治疗适应症组合，旨在证明它们在自身免疫和炎症性疾病中的疗效、安全性和给药便利性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250517012708aa2c91b2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250517012708aa2c91b2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ZURA"],"gpt_icon":0},{"id":"2535009879","title":"Zura Bio Limited盘中异动 下午盘股价大跌5.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2535009879","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2535009879?lang=zh_cn&edition=full","pubTime":"2025-05-15 02:13","pubTimestamp":1747246420,"startTime":"0","endTime":"0","summary":"北京时间2025年05月15日02时13分，Zura Bio Limited股票出现异动，股价大幅下跌5.37%。截至发稿，该股报1.15美元/股，成交量14.029万股，换手率0.21%，振幅6.20%。Zura Bio Limited股票所在的生物技术行业中，整体跌幅为1.22%。Zura Bio Limited公司简介：Zura Bio Ltd 是一家临床阶段的多资产免疫学公司，致力于开发针对自身免疫和炎症性疾病的新型双通路抗体。该公司正在开发 tibulizumab 和 torudokimab 的治疗适应症组合，旨在证明它们在自身免疫和炎症性疾病中的疗效、安全性和给药便利性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025051502134094f6fa33&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025051502134094f6fa33&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ZURA"],"gpt_icon":0},{"id":"2534766102","title":"Zura Bio Limited盘中异动 早盘股价大涨5.79%报1.28美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2534766102","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534766102?lang=zh_cn&edition=full","pubTime":"2025-05-12 21:32","pubTimestamp":1747056763,"startTime":"0","endTime":"0","summary":"北京时间2025年05月12日21时32分，Zura Bio Limited股票出现波动，股价急速上涨5.79%。Zura Bio Limited股票所在的生物技术行业中，整体涨幅为0.32%。Zura Bio Limited公司简介：Zura Bio Ltd 是一家临床阶段的多资产免疫学公司，致力于开发针对自身免疫和炎症性疾病的新型双通路抗体。消息层面，截至21时32分，《奥本海默：维持Zura Bio评级，由优于大市调整至优于大市评级, 目标价由19.00美元调整至17.00美元。》资讯为影响Zura Bio Limited的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025051221324394f481e1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025051221324394f481e1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ZURA"],"gpt_icon":0},{"id":"2534459634","title":"奥本海默：维持Zura Bio(ZURA.US)评级，由优于大市调整至优于大市评级, 目标价由19.00美元调整至17.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2534459634","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534459634?lang=zh_cn&edition=full","pubTime":"2025-05-10 01:53","pubTimestamp":1746813181,"startTime":"0","endTime":"0","summary":"奥本海默：维持Zura Bio(ZURA.US)评级，由优于大市调整至优于大市评级, 目标价由19.00美元调整至17.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/05/10015350281249.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["ZURA"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.zurabio.com","stockEarnings":[{"period":"1week","weight":0.1818},{"period":"1month","weight":0.0833},{"period":"3month","weight":0.1404},{"period":"6month","weight":-0.3333},{"period":"1year","weight":-0.6496},{"period":"ytd","weight":-0.48}],"compareEarnings":[{"period":"1week","weight":0.0067},{"period":"1month","weight":0.0466},{"period":"3month","weight":0.1622},{"period":"6month","weight":0.054},{"period":"1year","weight":0.1158},{"period":"ytd","weight":0.0661}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Zura Bio Limited成立于2022年1月。该公司是一家临床阶段、多资产免疫学公司，致力于为一系列未满足需求的自身免疫和炎症性疾病开发新型双通路抗体。凭借团队的丰富经验，公司识别相关疾病，并在这些疾病中开发差异化资产。公司战略重点是利用双通路生物的力量，为自身免疫性和炎症性疾病患者提供更广泛、更深层次的临床获益。","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.158249},{"month":2,"riseRate":0.75,"avgChangeRate":0.007816},{"month":3,"riseRate":0.5,"avgChangeRate":0.020185},{"month":4,"riseRate":0.75,"avgChangeRate":0.079189},{"month":5,"riseRate":0.25,"avgChangeRate":-0.072869},{"month":6,"riseRate":0.75,"avgChangeRate":0.041052},{"month":7,"riseRate":0.75,"avgChangeRate":0.051925},{"month":8,"riseRate":0.666667,"avgChangeRate":0.016862},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.018218},{"month":10,"riseRate":0.75,"avgChangeRate":-0.049536},{"month":11,"riseRate":0.75,"avgChangeRate":-0.066486},{"month":12,"riseRate":0.25,"avgChangeRate":-0.053882}],"exchange":"NASDAQ","name":"Zura Bio","nameEN":"Zura Bio"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.3","shortVersion":"4.34.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Zura Bio(ZURA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Zura Bio(ZURA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Zura Bio,ZURA,Zura Bio股票,Zura Bio股票老虎,Zura Bio股票老虎国际,Zura Bio行情,Zura Bio股票行情,Zura Bio股价,Zura Bio股市,Zura Bio股票价格,Zura Bio股票交易,Zura Bio股票购买,Zura Bio股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Zura Bio(ZURA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Zura Bio(ZURA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}